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Abstract: Importance Cardiovascular implanted electronic devices (CIEDs) are susceptible to electro-
magnetic interference. Dermatologists regularly use devices containing magnets, including dermatoscopes
and their attachments, which could pose a hazard to patients with CIEDs. Objective To investigate the
safety risk of magnets in dermatoscopes to patients with CIEDs. Design, Setting, and Participants This
cross-sectional observational study was conducted between January 1, 2018, and March 31, 2018, in a
controlled laboratory setting. Two experiments were performed. In the first experiment (performed in
the Dermatology Service at Memorial Sloan Kettering Cancer Center, New York), dermatoscopes that
contain magnets were obtained from 3 manufacturers. Using a magnometer, the magnetic field strength
of the dermatoscopes was measured over the magnet; at the faceplate; and at a distance of 0.5 cm, 1 cm
and 15 cm away from the faceplate. In the second experiment (performed in the University Heart Center
Zurich, Zurich, Switzerland), ex vivo measurements were conducted to determine how the dermatoscopes
affected old-generation and new generation CIEDs (pacemakers and implantable defibrillators). Main
Outcomes and Measures Magnetic field strength as measured directly over the dermatoscope magnet; at
the faceplate; and at distances of 0.5 cm, 1 cm, and 15 cm from the faceplate. Pacemaker and defibrillator
operation when exposed to dermatoscopes. Results After conducting 24 measurements, the magnetic field
(measured in gauss [G]) strength varied between 24.26 G and 163.04 G over the dermatoscope magnet,
between 2.22 G and 9.98 G at the dermatoscope faceplate, between 0.82 G and 2.4 G at a distance of
0.5 cm, and between 0.5 G and 1.04 G at a distance of 1 cm; it was 0 for all devices at a 15 cm distance.
The field strength at the faceplate was found to be generally below the CIED industry standard safety
threshold. None of the dermatoscopes in the ex vivo experiment exerted any demonstrable disruptions or
changes to the CIEDs. Conclusions and Relevance In real life, dermatoscope magnets likely present no
measurable safety risk to patients with CIEDs. Using the polarized noncontact mode permits dermoscopy
to be performed at least 0.5 cm from the skin surface, where the magnetic field strength was well below
the 5-G safety threshold.
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IMPORTANCE Cardiovascular implanted electronic devices (CIEDs) are susceptible to
electromagnetic interference. Dermatologists regularly use devices containing magnets,
including dermatoscopes and their attachments, which could pose a hazard to patients with
CIEDs.
OBJECTIVE To investigate the safety risk of magnets in dermatoscopes to patients with
CIEDs.
DESIGN, SETTING, AND PARTICIPANTS This cross-sectional observational studywas conducted
between January 1, 2018, andMarch 31, 2018, in a controlled laboratory setting. Two
experiments were performed. In the first experiment (performed in the Dermatology Service
at Memorial Sloan Kettering Cancer Center, New York), dermatoscopes that contain magnets
were obtained from 3manufacturers. Using a magnometer, the magnetic field strength of the
dermatoscopes wasmeasured over themagnet; at the faceplate; and at a distance of 0.5 cm,
1 cm and 15 cm away from the faceplate. In the second experiment (performed in the
University Heart Center Zurich, Zurich, Switzerland), ex vivomeasurements were conducted
to determine how the dermatoscopes affected old-generation and new generation CIEDs
(pacemakers and implantable defibrillators).
MAIN OUTCOMES ANDMEASURES Magnetic field strength asmeasured directly over the
dermatoscopemagnet; at the faceplate; and at distances of 0.5 cm, 1 cm, and 15 cm from the
faceplate. Pacemaker and defibrillator operation when exposed to dermatoscopes.
RESULTS After conducting 24measurements, the magnetic field (measured in gauss [G])
strength varied between 24.26 G and 163.04 G over the dermatoscopemagnet, between
2.22 G and 9.98 G at the dermatoscope faceplate, between 0.82 G and 2.4 G at a distance of
0.5 cm, and between 0.5 G and 1.04 G at a distance of 1 cm; it was 0 for all devices at a 15 cm
distance. The field strength at the faceplate was found to be generally below the CIED
industry standard safety threshold. None of the dermatoscopes in the ex vivo experiment
exerted any demonstrable disruptions or changes to the CIEDs.
CONCLUSIONS AND RELEVANCE In real life, dermatoscopemagnets likely present no
measurable safety risk to patients with CIEDs. Using the polarized noncontact mode permits
dermoscopy to be performed at least 0.5 cm from the skin surface, where themagnetic field
strength was well below the 5-G safety threshold.
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C ardiovascular implantedelectronic devices (CIEDs) aresusceptible to electromagnetic interference (EMI); thatis, their operation is disruptedwhen they are exposed
toanelectromagnetic field.Electromagnetic interferencecould
potentially result in asynchronous or nonphysiological pac-
ing in pacemakers and could deactivate tachytherapies in
defibrillators.1 This outcome is usually temporary, although
permanent shutdownof adefibrillatorhasbeen reported.2Ac-
cording to various CIEDmanufacturers, the strength of mag-
netic fields interacting with CIEDs (measured in gauss [G])
should not exceed the industry standard of 5 G to 10 G.3-5
Various devices that contain magnets are regularly used
by clinicians, including dermatoscopes, cellular phones, and
computer tablets. Some of these devices could theoretically
affect the functionality of CIEDs. In a study, the Apple iPad 2
triggered themagnetmode inaCIEDwhen laidontheskinover
thedevice.6As a general precaution, somemanufacturers ad-
vise keeping a distance of 15 cm between CIEDs and cellular
phones or computer tablets.4,7 Recently, the US Department
of Veterans Affairs National Center for Patient Safety (NCPS)
recounted this issue and requested data regarding magnet
strength from major dermatoscope manufacturers. Accord-
ingly, theNCPS calculated a distance of 0.3 cm to 2.9 cm from
the dermatoscopes at which the 5-G threshold would theo-
retically be reached. Additionally they estimated the mag-
netic field strength to range from 0.0002 G to 0.18 G at a dis-
tance of 15 cm from the dermatoscopes. The NCPS issued a
safety notification that recommended maintaining a dis-
tance of at least 15 cm between a CIED and a dermatoscope,
computer tablet, or other magnet-containing devices. The 15
cmdistance recommendation incorporates a large safety fac-
tor and provides guidance consistent with the recommenda-
tions for cellular phones and computer tablets. The National
Center for Patient Safety itself did not perform any testing on
dermatoscopesandCIEDs, and its recommendationsarebased
solely on calculations using industry data. Both skin cancer
rates andCIEDprevalence are increasing, particularly inwhite
males older than 65 years.8,9 Hence, encountering suspected
skin lesions in thevicinity of CIEDs is likely to be anevermore
frequent scenario. The purpose of this study was to investi-
gate the safety risk of magnets in dermatoscopes to patients
with CIEDs.
Methods
This study did not involve human subjects and, according to
standard operating practice atMemorial SloanKettering Can-
cer Center, is therefore not in the purview of the institutional
review board. We conducted the study between January 1,
2018, and March 31, 2018.
We approached 3 major dermatoscope manufacturers
(3Gen, Canfield Scientific Inc, and Heine Optotechnik) for a
list of all of their dermatoscope models that contain mag-
nets. Accordingly, we obtained 1 of each dermatoscope
device (DermLite DL4 and DL4w [3Gen], VEOS HD1 and
HD2 [Canfield Scientific Inc], and NC1 and NC2 [Heine Opto-
technik]) for testing purposes. The first experiment was
performed in the Dermatology Service, Memorial Sloan
Kettering Cancer Center, New York. Using a magnometer
(PCE-MFM 3000; PCE Americas), we measured the G
strength of these dermatoscopes at the faceplate and at a
distance of 0.5 cm, 1 cm, and 15 cm from the faceplate. In
addition, after removal of the faceplate, we measured the
gauss strength directly over the magnet of each dermato-
scope. We calculated the mean value of 5 repetitive mea-
surements for each device and each magnet.
We performed a second set of experiments in a con-
trolled laboratory setting (University Heart Center Zurich,
Zurich, Switzerland) to determine how magnets in dermato-
scopes affect ex vivo CIED functionality. These experiments
entailed placing dermatoscopes (DL4 and VEOS HD1 and
HD2) in contact with both old-generation (Cylos 990 DR
pacemaker and Lumax 540 DR-T defibrillator; Biotronik)
and new-generation (Biotronik Edora 8 DR-T pacemaker and
Ilivia 7 HF-t defibrillator; Biotronik) CIEDs. We monitored
the functionality of the device by visualization on a cardiac
monitor. We placed each dermatoscope in contact with the
CIED for 30 seconds and repeated this task 25 times for each
CIED. We also placed a magnet (Biotronik), designed to
intentionally induce the magnet mode in CIEDs, on the
same CIED for 30 seconds.
Results
The magnetic field strength measurements over the magnet
varied between 24.26 and 163.04 G. The measurements at
the faceplate varied between 2.22 and 9.98 G. The magnetic
field strength continued to decrease when the distance from
the faceplate increased, varying between 0.82 G and 2.4 G
at 0.5 cm, between 0.5 G and 1.04 G at 1 cm, and 0 for all
devices at 15 cm (Table; Figure).
None of the tested dermatoscopes exerted any demon-
strable force on the pacemakers and defibrillators after
repetitive 30-second exposures. Exposure of these CIEDs to
the Biotronik cardiologic magnet immediately shut down
the defibrillators’ tachycardia function and put the pace-
makers in safe mode (ie, 70 beats per second).
Key Points
Question Canmagnets in dermatoscopes pose a safety risk to
patients with cardiovascular implanted electronic devices?
Findings In this cross-sectional study of 3 different dermatoscope
models, the magnetic field measured directly above themagnets
in each device was stronger than themanufacturer-recommended
5 gauss to 10 gauss threshold. However, the gauss readings at the
faceplate of these devices were either substantially low or below
the 5-gauss safety threshold.
Meaning In real life, dermatoscopemagnets likely present no
measurable adverse outcomes in patients with cardiovascular
implanted electronic devices.
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Discussion
Toappreciate the likely riskofmagnets topatientswithCIEDs,
onemustunderstandhowmagnetic fields aremeasured.Mag-
netic field strength is calculated by the following formula:
Φ = BAcosθ, where B is the flux density (gauss per area unit),
A is the surface area, and θ is the magnet’s spatial
configuration.10 The flux density (B) is constant for themate-
rial of the magnet and therefore serves as the most practical
measure of magnetic field strength. In contrast, A is the size
of the magnet and θ is its spatial orientation. A large magnet
generally creates stronger magnetic fields compared with a
smallmagnetmadeof thesamematerial.11Hence, the fluxden-
sity of a 5G to 10Gwouldhave aweaker andweaker pull force
as the size of themagnet decreases. In addition, themagnetic
field strength decreases as an inverse square function of the
distance fromthesource.1Accordingly, adistanceofonlya few
millimeters away fromtheCIEDcould substantially reduce the
electromagnetic interference.
In our study, all themagnetic field readings taken over the
magnetswerestrongerthantherecommended5Gto10Gthresh-
old.However,thereadingatthefaceplatewassubstantiallylower,
andthe readings formostdermatoscopesweresafelybelowthe
5-G threshold. ForVEOSHD1 andHD2, ameasure below 10G is
generallyconsideredstill safebymany investigators.1,3,4,6Thus,
thesmallsizeofthemagnetsinthetesteddermatoscopesandthe
fewcentimeters’recessbetweenthemagnetandthefaceplateex-
plainthemeasurementdifferencesbetweenreadingsattheface-
plateandover themagnet.Atadistanceofa0.5cm,which is the
approximate distance from the skinwhennoncontact dermos-
copymodeisused, themagnetic fieldstrengthwascategorically
belowthesafetythresholdforalldevicestested.Consistently,we
observednodisruptionsorchanges toexvivoCIEDsfromanyof
thetesteddermatoscopesafterprolongedexposures inthe labo-
ratory and evenwhen exposed to old-generationCIEDs,which
aregenerallymoresusceptible toelectromagnetic interference.1
Integration of the 2 parts of our study suggests that rely-
ing solely on the gauss measure of the magnet in dermato-
scopes may result in the overestimation of the risk they pose
to patients with CIEDs. Furthermore, the 15 cm distance rule
is evidently an excessive precaution and is an impractical dis-
tance for dermoscopy application. In real-life scenarios,
dermatoscopes likely present no measurable adverse out-
comes for patients with CIEDs.
Note thatwedidnot testdermatoscopicattachments, such
as cameras, cellular phones, or computer tablets. These de-
vices likelycontain largerandstrongermagnets.Weadvise that
they not be used within 15 cm of a CIED until they have been
further tested. Moreover, other implanted devices (eg, cere-
brospinal fluid shunts) may require similar precautions.12
Limitations
A limitation of this study is that it did not involve human par-
ticipation. The entire study was conducted in a laboratory.
Conclusions
Onthebasis of our literature reviewandexperiments,weposit
the following 4 recommendations when examining skin
lesions in the vicinity of CIEDs:
1. Use dermatoscopes that do not contain magnets, if
available.
2. Use polarized noncontact dermoscopymode, given that as
little as a 0.5 cm distance substantially reduces magnetic
field strength.
3. Do not remove the faceplate because it provides addi-
tional distance and potential shielding.
4. Avoid using dermatoscopic attachments (such as cameras,
cellular phones, or computer tablets) near CIEDs because
the magnets in these devices are generally stronger than
those in dermatoscopes.
This study revealed that the magnets in the 3 tested
dermatoscopes had a lowmagnetic field strength at the face-
plate and showed nomeasurable effects on CIEDs.
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Magnetic field strength of dermatoscopes (DL4 and 4W, NC1 and NC2,
and VEOS HD1 and HD2) as measured over themagnet; at the faceplate;
and at a 0.5 cm, 1 cm, and 15 cm distance from the faceplate.
Table. Mean Gauss Reading for Tested Dermatoscopes
Dermato-
scope
Reading, Mean (SD), G
Over Magnet At Faceplate
0.5 cm Distance
From Faceplate
1 cm Distance
From Faceplate
15 cm Distance
From Faceplate
DL4 and 4w 110.38 (18.2) 2.58 (0.18) 0.82 (0.15) 0.5 (0) 0 (0)
NC1 and NC2 163.04 (25.2) 2.22 (0.24) 1.5 (0.19) 1.04 (0.08) 0 (0)
VEOS HD1
and HD2
24.26 (3.2) 9.98 (0.52) 2.4 (0.12) 1 (0) 0 (0)
Abbreviation: G, gauss.
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